ES2720869T3 - Composiciones farmacéuticas de sevelámero - Google Patents

Composiciones farmacéuticas de sevelámero Download PDF

Info

Publication number
ES2720869T3
ES2720869T3 ES09741235T ES09741235T ES2720869T3 ES 2720869 T3 ES2720869 T3 ES 2720869T3 ES 09741235 T ES09741235 T ES 09741235T ES 09741235 T ES09741235 T ES 09741235T ES 2720869 T3 ES2720869 T3 ES 2720869T3
Authority
ES
Spain
Prior art keywords
sevelamer
percent
pharmaceutical compositions
weight
nucleus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09741235T
Other languages
English (en)
Inventor
Niels Osinga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Application granted granted Critical
Publication of ES2720869T3 publication Critical patent/ES2720869T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un comprimido farmacéutico de liberación inmediata con un núcleo que comprende el 70-85 por ciento en peso de carbonato de sevelámero, calculado como un compuesto anhidro, el 10-25 por ciento en peso de monohidrato de lactosa y, opcionalmente, una capa de película soluble en agua rodeando el núcleo, en donde la composición está libre de celulosa cristalina y de hidroxipropilcelulosa (poco sustituida) u otros agentes de unión.
ES09741235T 2009-10-22 2009-10-22 Composiciones farmacéuticas de sevelámero Active ES2720869T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/007586 WO2011047700A1 (en) 2009-10-22 2009-10-22 Pharmaceutical compositions of sevelamer

Publications (1)

Publication Number Publication Date
ES2720869T3 true ES2720869T3 (es) 2019-07-25

Family

ID=42044436

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09741235T Active ES2720869T3 (es) 2009-10-22 2009-10-22 Composiciones farmacéuticas de sevelámero

Country Status (7)

Country Link
US (1) US20120219626A1 (es)
EP (1) EP2490675B1 (es)
DK (1) DK2490675T3 (es)
EA (1) EA024699B1 (es)
ES (1) ES2720869T3 (es)
WO (1) WO2011047700A1 (es)
ZA (1) ZA201203719B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
AU2014274817B2 (en) 2013-06-05 2019-05-23 Tricida, Inc. Proton-binding polymers for oral administration
ES2857177T3 (es) 2014-12-10 2021-09-28 Tricida Inc Polímeros de unión de protones para administración oral
EP3261624A1 (en) * 2015-02-23 2018-01-03 Amneal Pharmaceuticals Company GmbH Process for granulating sevelamer carbonate
SG11201809605PA (en) 2016-05-06 2018-11-29 Tricida Inc Compositions for and method of treating acid-base disorders
SG11202003451UA (en) 2017-11-03 2020-05-28 Tricida Inc Compositions for and method of treating acid-base disorders
CN110664772A (zh) * 2019-09-27 2020-01-10 方达医药技术（苏州）有限公司 一种碳酸司维拉姆片及其制备方法
CN111773190A (zh) * 2020-06-24 2020-10-16 北京瑞迪道森医药科技有限公司 一种提高制剂安全性的碳酸司维拉姆片及其制备方法
CN112220762B (zh) * 2020-09-07 2022-08-19 湖北华世通生物医药科技有限公司 碳酸司维拉姆包衣片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW592727B (en) * 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
AU778262B2 (en) * 1999-10-19 2004-11-25 Genzyme Corporation Direct compression polymer tablet core
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
WO2007094779A1 (en) * 2006-02-14 2007-08-23 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
WO2009034540A1 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Pharmaceutical composition of sevelamer
DE102008030046A1 (de) * 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers

Also Published As

Publication number Publication date
EP2490675B1 (en) 2019-01-23
EA201270581A1 (ru) 2012-12-28
ZA201203719B (en) 2013-08-28
DK2490675T3 (en) 2019-04-29
EA024699B1 (ru) 2016-10-31
US20120219626A1 (en) 2012-08-30
EP2490675A1 (en) 2012-08-29
WO2011047700A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
ES2720869T3 (es) Composiciones farmacéuticas de sevelámero
PE20120250A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano, forma farmaceutica de la misma, procedimiento para su preparacion
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
MX2012003082A (es) Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
NZ597237A (en) Sublingual apomorphine
HK1139854A1 (en) Fast-dissolving disintegrating film preparation having high proportion of active agent
BRPI0719395C1 (pt) tablete revestido de filme
BR112013006597A2 (pt) tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo
MY162940A (en) Quinoline derivative-containing pharmaceutical composition
PE20131102A1 (es) Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
EA201270216A1 (ru) Фармацевтический состав
BRPI1014527B8 (pt) composição farmacêutica na forma de lipossoma e método de fabricação da mesma
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
AR081670A1 (es) Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
UY32624A (es) Procedimiento y composición para mejorar la absorción de agentes terapéuticos
CR20110209A (es) Composición farmacéutica sólida
CL2012003011A1 (es) Comprimido de desintegracion por via oral que contiene un 1-30 % de acarbosa, un 40-90 % de un vehiculo soluble en agua y un 1-50 % de un vehiculo soluble en agua, para el tratamiento de diabetes mellitus; y procedimiento para preparar comprimidos de desintegracion oral que contienen acarbosa.
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
BR112013000300A2 (pt) comprimido que se desintegra intraoralmente
AR087787A1 (es) Compuesto de benzotiazolona